Sartorius Stedim Biotech's quarterly market cap
increased
from Sep. 2025 ($21,440 Mil) to Dec. 2025 ($23,127 Mil) but then
declined
from Dec. 2025 ($23,127 Mil) to Mar. 2026 ($18,736 Mil).
Sartorius Stedim Biotech's annual market cap
declined
from Dec. 2023 ($25,281 Mil) to Dec. 2024 ($19,119 Mil) but then
increased
from Dec. 2024 ($19,119 Mil) to Dec. 2025 ($23,127 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Sartorius Stedim Biotech's Enterprise Value for Today is $21,976 Mil.
Sartorius Stedim Biotech (OTCPK:SRTOY) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Sartorius Stedim Biotech Market Cap Related Terms
Sartorius Stedim Biotech Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Sartorius Stedim Biotech's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sartorius Stedim Biotech Market Cap vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sartorius Stedim Biotech's Market Cap distribution charts can be found below:
* The bar in red indicates where Sartorius Stedim Biotech's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Sartorius Stedim Biotech's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sartorius Stedim Biotech (SRTOY) has a Market Cap of $19,543 Mil as of Jun. 27, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Sartorius Stedim Biotech and its competitors. According to the industry distribution chart, Sartorius Stedim Biotech ranks #22 out of 866 companies in the Medical Devices & Instruments industry, placing it in the top 2.5%.
Is Sartorius Stedim Biotech's Market Cap too high?
Sartorius Stedim Biotech's current Market Cap is $19,543 Mil. The Medical Devices & Instruments industry median Market Cap is 121.29. Sartorius Stedim Biotech's value of $19,543 Mil is 16012.6% above this industry median. Based on the distribution chart, Sartorius Stedim Biotech ranks #22 out of 866 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Sartorius Stedim Biotech has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sartorius Stedim Biotech's Market Cap compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sartorius Stedim Biotech ranks #22 out of 866 companies for Market Cap. This places Sartorius Stedim Biotech in the top 3% of its industry — outperforming the majority of peers. The industry median Market Cap is 121.29. Sartorius Stedim Biotech's value of $19,543 Mil is 16012.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Devices & Instruments company?
The median Market Cap among Medical Devices & Instruments companies is 121.29, based on 866 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sartorius Stedim Biotech's current Market Cap of $19,543 Mil is 16012.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Sartorius Stedim Biotech and its competitors. For the Medical Devices & Instruments industry, the median Market Cap is 121.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sartorius Stedim Biotech's current Market Cap is $19,543 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius Stedim Biotech stock overvalued right now?
Based on GuruFocus' analysis, Sartorius Stedim Biotech (SRTOY) is currently considered Modestly Undervalued. The stock's GF Value™ is $23.65, compared to a current price of $20.09 — trading 15.1% below its estimated fair value. The current Market Cap is $19,543 Mil and 16012.6% above the Medical Devices & Instruments industry median of 121.29. Sartorius Stedim Biotech's overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Sartorius Stedim Biotech (SRTOY), the current Market Cap is $19,543 Mil as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sartorius Stedim Biotech (SRTOY) Overvalued in 2026?
Based on GuruFocus' analysis, Sartorius Stedim Biotech stock appears to be undervalued.
The current stock price of $20.09 is trading 15.1% below its estimated GF Value™ of $23.65.
GuruFocus considers Sartorius Stedim Biotech to be Modestly Undervalued.
Key valuation signals for SRTOY:
Market Cap: $19,543 Mil
GF Value™: $23.65 vs. price of $20.09 (15.1% below fair value)
Industry Position: 16012.6% above the Medical Devices & Instruments median (#22 of 866)
No single metric tells the full story. See the SRTOY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. It sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.
82GF Score
Get the complete analysis for SRTOY
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SRTOY has been successfully added to your 
